| Literature DB >> 24804199 |
Kalpesh Gohel1, Amit Jojera1, Shailesh Soni1, Sishir Gang1, Ravindra Sabnis1, Mahesh Desai1.
Abstract
Blood stream infections can lead to life threatening sepsis and require rapid antimicrobial treatment. The organisms implicated in these infections vary with the geographical alteration. Infections caused by MDR organisms are more likely to increase the risk of death in these patients. The present study was aimed to study the profile of organisms causing bacteremia and understand antibiotic resistance patterns in our hospital. 1440 blood samples collected over a year from clinically suspected cases of bacteremia were studied. The isolates were identified by standard biochemical tests and antimicrobial resistance patterns were determined by CLSI guidelines. Positive blood cultures were obtained in 9.2% of cases of which Gram-positive bacteria accounted for 58.3% of cases with staph aureus predominance; gram negative bacteria accounted for 40.2% with enterobactereciea predominence; and 1.5% were fungal isolates. The most sensitive drugs for Gram-positive isolates were vancomycin, teicoplanin, daptomycin, linezolid, and tigecycline and for Gram-negative were carbapenems, colistin, aminoglycosides, and tigecycline. The prevalence of MRSA and vancomycin resistance was 70.6% and 21.6%, respectively. ESBL prevalence was 39.6%. Overall low positive rates of blood culture were observed.Entities:
Mesh:
Year: 2014 PMID: 24804199 PMCID: PMC3997982 DOI: 10.1155/2014/153747
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Distribution of isolates in blood cultures.
| Type | Numbers | Percentage |
|---|---|---|
|
| 51 | 38.6 |
|
| 20 | 15.2 |
|
| 13 | 9.8 |
|
| 7 | 5.3 |
|
| 7 | 5.3 |
|
| 7 | 5.3 |
|
| 6 | 4.5 |
| Coagulase-negative staphylococci | 6 | 4.5 |
|
| 5 | 3.8 |
|
| 4 | 3.0 |
|
| 2 | 1.5 |
|
| 2 | 1.5 |
|
| 1 | 0.8 |
|
| 1 | 0.8 |
Drug resistance pattern of major Gram-positive isolates.
| Antimicrobial tested |
|
| ||
|---|---|---|---|---|
| Mini API ( | Vitek ( | Mini API ( | Vitek ( | |
| Amoxicillin | NP | NP | 100 | 100 |
| Cefotaxime + clavulanate | NP | 50 | NP | 37 |
| Ceftazidime + clavulanate | NP | 50 | NP | 37 |
| Cefepime + tazobactam | NP | 50 | NP | 30 |
| Tigecycline | NP | 0 | NP | NP |
| Gentamycin | 33 | 50 | NP | NP |
| Amikacin | 33 | 50 | NP | NP |
| Ciproflox | 100 | 100 | 90 | 87 |
| Levoflox | 100 | 100 | 75 | 80 |
| Nalidixic acid | 100 | 100 | NP | NP |
| Nitrofurantoin | 100 | 100 | 0 | 78 |
| Tetracycline | 33 | 50 | 10 | 27 |
| Doxycycline | 33 | 50 | 10 | 27 |
| Minocycline | 33 | 50 | 10 | 27 |
| Oxacillin | NP | NP | 73 | 67 |
| Vancomycin** | 50 | 50 | 20 | 22 |
| Teicoplanin | 33 | 50 | NP | 0 |
| Daptomycin | NP | 0 | NP | 6 |
| Linezolid | NP | 0 | NP | 3 |
NP: drug not in panel; **see Section 4.
Figures in the table are expressed in percentages.
Drug resistance pattern of major Gram-negative isolates.
| Antimicrobial tested |
|
|
| ||
|---|---|---|---|---|---|
| Mini API ( | Vitek ( | Vitek ( | Mini API ( | Vitek ( | |
| Amoxicillin | 92 | 100 | 100 | 100 | 100 |
| Ceftriaxone | 92 | 100 | 100 | 100 | 100 |
| Ceftazidime | 92 | 87.50 | 92 | 0 | 67 |
| Cefepime | 84 | 75 | 92 | 0 | 50 |
| Amoxicillin + clavulanate | 84 | 100 | 100 | 100 | 100 |
| Cefotaxime + clavulanate | 40 | 37.50 | 72 | 100 | 83 |
| Ceftazidime + clavulanate | 40 | 37.50 | 54 | 100 | 67 |
| Ticarcillin + clavulanate | 58 | NP | NP | 0 | NP |
| Piperacillin + tazobactam | 50 | 50 | 77 | 0 | 33 |
| Cefoperazone + sulbactam | NP | 12.50 | 62 | NP | 33 |
| Cefepime + tazobactam | NP | 37.50 | 54 | NP | 33 |
| Imipenem | 10 | 0 | 54 | 0 | 33 |
| Meropenem | 10 | 12.50 | 70 | 0 | 33 |
| Ertapenem | NP | NP | 62 | NP | NP |
| Colistin | NP | 0 | 8 | 0 | 0 |
| Tigecycline | NP | 0 | 54 | NP | 67 |
| Gentamycin | 42 | 37.50 | 54 | 0 | 33 |
| Amikacin | 30 | 12.50 | 46 | 0 | 33 |
| Ciproflox | 92 | 87.50 | 77 | 0 | 33 |
| Levoflox | 92 | 87.50 | 77 | 0 | 33 |
| Nalidixic acid | 92 | 87.50 | 84 | NP | NP |
| Nitrofurantoin | 58 | 70 | 84 | 100 | 83 |
| Tetracycline | 75 | 75 | 84 | 100 | 83 |
| Doxycycline | 75 | 75 | 84 | 100 | 83 |
| Minocycline | 75 | 75 | 84 | 100 | 83 |
Figures are in percentage; N.P: drug not in panel; ##all the Klebsiella isolates were tested on Vitek 2.